Objective: To identify clinical and radiological factors associated to early evolution to brain death (BD), defined as occurring within the first 24 h.
Design: A retrospective cohort study was made covering the period 2015-2017.
Setting: An adult Intensive Care Unit (ICU).
The most severe clinical manifestations of the Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are due to an unbalanced immune response and a pro-thrombotic hemostatic disturbance, with arterial hypertension or diabetes as acknowledged risk factors. While waiting for a specific treatment, the clinical management of hospitalized patients is still a matter of debate, and the effectiveness of treatments to manage clinical manifestations and comorbidities has been questioned. In this study, we aim to assess the impact of the clinical management of arterial hypertension, inflammation and thrombosis on the survival of COVID-19 patients.
View Article and Find Full Text PDFObjective: To identify clinical and radiological factors associated to early evolution to brain death (BD), defined as occurring within the first 24 hours.
Design: A retrospective cohort study was made covering the period 2015-2017.
Setting: An adult Intensive Care Unit (ICU).
Objective: To evaluate the clinical impact of Meningitis/Encephalitis FilmArray® panel for the diagnosis of cerebral nervous system infection and to compare the results (including time for diagnosis) with those obtained by conventional microbiological techniques.
Methods: A prospective observational study in an Intensive Care Unit of adults from a tertiary hospital was carried out. Cerebrospinal fluid from all patients was taken by lumbar puncture and assessed by the meningitis/encephalitis FilmArray® panel ME, cytochemical study, Gram, and conventional microbiological cultures.